Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates.
I.v. administration of U-50,488H after i.v. saline pretreatment produced occasional high-voltage EEG slow-wave bursts that were associated with relatively small increases in spectral power in the 2.5-7.5 Hz band as a spectral peak and with behavioral incidents of sedation, ataxia, ptosis, straub tail, hunching of the back, and backing-up. After pretreatment with the sigma antagonists rimcazole and DuPont Merck S-7389-4, U-50,488H administration produced significantly larger increases in absolute EEG spectral power, both over the 1-50 Hz range and in the 2.5-5.0 and 5.0-7.5 Hz bands, than after saline pretreatment; rimcazole pretreatment eliminated U-50,488H-induced incidents of ataxia, ptosis, hunching of the back and backing-up. In summary, effects of U-50,488H on EEG, EEG power spectra and behavior may reflect interactions between kappa opioid and sigma (non-opioid) receptor-effector systems.
Young
G A
GA
Department of Pharmacology and Toxicology, University of Maryland School of Pharmacy, Baltimore 21201.
Hudson
G M
GM
Stamidis
H
H
Steinfels
G F
GF
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D002227:Carbazoles / Q000494:pharmacology*; D004347:Drug Interactions; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D007275:Injections, Intravenous; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017480:Receptors, sigma / Q000037:antagonists & inhibitors*
D000959:Antihypertensive Agents; D014150:Antipsychotic Agents; D002227:Carbazoles; D011759:Pyrrolidines; D017480:Receptors, sigma; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; C034931:rimcazole